Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice – safety and efficacy in basal bolus regimen)

Czech version

Authors: Denisa Janíčková Žďárská ¹; Jan Brož ¹; Bohumila Křivská ²; Zdeněk Rušavý ³; Milan Kvapil ¹
Authors‘ workplace: Interní klinika 2. LF UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA ¹; Sanofi-Aventis, s. r. o., Praha ²; I. interní klinika LF UK a FN Plzeň, přednosta prof. MUDr. Martin Matějovič, Ph. D. ³
Published in: Vnitř Lék 2014; 60(9): 712-719
Category:

Overview

Objective:
To evaluate the safety and efficacy of basal insulin glargine using a basal-bolus regimen in a common clinical practice setting in the Czech Republic.

Patients and methods:
The LINDA project was a non-interventional, multicenter (n = 255), national, observational project. A total of 4,998 patients with Type 1 and 2 diabetes mellitus (T1DM, T2DM) with predominantly insulin therapy (99,7 %), after switch on insulin glargine at basal-bolus regimen, were enrolled in this project. The patients were followed up for 6 months after initiation of the therapy with insulin glargine. The primary objective of the project was to investigate the incidence of severe hypoglycemic episodes during the treatment with basal insulin analogue glargine (Lantus^®) in a common clinical practice setting. The secondary endpoints were changes in glycosylated hemoglobin (HbA_1c) levels, fasting plasma glucose (FPG), body weight, insulin dose, change of number of hypoglycemic episodes in comparison the previous therapy and the frequency of adverse effects.

Results:
Severe hypoglycaemia were observed during treatment with insulin glargine at 0.8 % patients. When comparing the incidence of hypoglycemia with the previous therapy, we demonstrated a clinically and statistically significant reduction in their frequencies. The percentage of patients with hypoglycemic episodes (17.6 %), severe hypoglycemia (0.8 %) and severe nocturnal hypoglycemia (0.3 %) over the last month of treatment with insulin glargine using the basal-bolus regimen was consistently lower compared to the last month of treatment before initiation of this therapy (42.5 %, 17.6 %, and 13.8 % of the patients, respectively). In patients with T1DM, the incidence of hypoglycemia decreased from 37.80 ± 15.95 episodes/patient/year to 8.76 ± 4.38 episodes/patient/year (p < 0.001) for all hypoglycemic episodes; from 5.64 ± 3.27 episodes/patient/year to 0.0396 ± 0.012 episodes/patient/year (p < 0.001) for severe hypoglycemia; and from 3.84 ± 2.04 episodes/patient/year to 0.0096 ± 0.003 episodes/patient/year (p < 0.001) for severe nocturnal hypoglycemia. In patients with T2DM, the incidence of hypoglycemia decreased from 12.48 ± 7.57 episodes/patient/year to 1.68 ± 0.78 episodes/patient/year (p < 0.001) for all hypoglycemic episodes; from 2.04 ± 0.94 episodes/patient/year to 0.0132 ± 0.005 episodes/patient/year (p < 0.001) for severe hypoglycemia; and from 1.32 ± 0.77 episodes/patient/year to 0.0048 ± 0.0008 episodes/patient/year (p < 0.001) for severe nocturnal hypoglycemia. A statistically significant improvement in the metabolic control was demonstrated when using insulin glargine. The glycated hemoglobin (HbA_1c) decreased from 7.74 ± 1.71 % to 6.43 ± 1.39 % (∆ -1.31 ± 0.32 %, p < 0.001) in patients with T1DM, and from 8.13 ± 1.56 % to 6.72 ± 1.40 % (∆ -1.41 ± 0.28 %, p < 0.001) in patients with T2DM. A statistically significant (p < 0.001) increase in the number of patients with HbA_1c < 5.4 % was further demonstrated. The decrease in fasting blood glucose (FBG) and 6-point blood sugar profile was also statistically significant in both types of diabetes (p < 0.001). Changes in therapy and subsequent treatment with insulin glargine were perceived positively by both physicians and patients.

Conclusion:
In the common clinical practice setting, the initiation of treatment with insulin glargine using the basal-bolus regime in patients with previous insulin therapy resulted in a reduction in the incidence of hypoglycemic events, including severe hypoglycemia and severe nocturnal hypoglycemia, and improved metabolic control in patients with diabetes (reduced glycated hemoglobin, fasting glucose values and 6-point blood glucose profile). Greater satisfaction with the current treatment was reported by both patients and physicians.

Key words:
basal-bolus regimen – diabetes mellitus – insulin glargine – observational project

Sources

1. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11(4): 372–378.

2. Singh SR, Ahmad F, Lal A et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta analysis. CMAJ 2009; 180(4): 385–395.

3. Bazzano LA, Lee LJ, Shi L et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008; 25(8): 924–932.

4. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008; 81(2): 184–189.

5. Sharplin P, Gordon J, Peters JR et al. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 2009; 8: 3. Dostupné z DOI: <http://doi: 10.1186/1475–2840–8-3>.

6. Yki-Järvinen H, Dressler A, Zieman M Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23(8): 1130–1136.

7. Zdarska DJ, Kvapil M, Rusavy Z et al. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study. Wien Klin Wochenschr 2014; 126(7–8): 228–237.

8. Davies M, Lavalle-Gonza F, Stormset F et al. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008; 10(5): 387–399.

9. Hanefeld M, Bramlage P. Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr Diab Rep 2013; 13(3): 342–349.

10. Rusavý Z, Lacigová S, Kvapil M. What has the largest study in the history of diabetology brought us? Vnitř Lék 2013; 59(3): 160–164.

11. Gilbert RE, Mann JF, Hanefeld M et al (The ORIGIN trial investigators). Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 2014; 57(7): 1325–1331.

12. Siegmund T, Weber S, Blankenfeld H et al. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 2007; 115(6): 349–353.

13. Maia FF, Melo FJ, Araujo IM et al. Switching of NPH insulin to glargine therapy in a cohort of poorly controlled diabetic patients: observational study. Arq Bras Endocrinol Metab 2007; 51(3): 426–430.

14. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080–3086.

15. Porcellati F, Rossetti P, Pampanelli S et al. Better long-term glycemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21: 1213–1220.

16. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005; 35(9): 536–542.

17. Chatterjee S, Jarvis-Kay J, Rengarajan T et al. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes-the glargine and aspart study (GLASS) a randomized cross-over study. Diabetes Res Clin Pract 2007; 77(2): 215–222.

18. Pieber TS, Eugenie-Jolchine I, Derobert E Efficacy and Safety of HOE 901 Versus NPH insulin in Patients With Type1 Diabetes. Diabetes Care 2000; 23(2): 157–162.

19. Rossetti P, Pampanelli S, Fanelli C et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and Glargine insulin at dinner or bedtime. Diabetes Care 2003; 26(5): 1490–1496.

20. Sharplin P, Gordon J, Peters JR et al. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 2009; 8: 3. Dostupné z DOI: <http://doi: 10.1186/1475–2840–8-3>.

21. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49(3): 442–451.

22. Davies M, Evans R, Storms F et al. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Diabetes Obes Metab 2007; 9(5): 706–713.

23. Yki-Järvinen H, Juurinen L, Alvarsson M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30(6): 1364–1369.

24. Gomis R, Storms F, Conget I et al (AT.LANTUS Study Group). Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Res Clin Pract 2007; 77(1): 84–91.

25. Schreiber S, Landgraf W, Bohler S. Efficacy and tolerability of insulin glargine in ICT. Diabetes, Stoffwechsel und Herz 2009; 18(8): 91–98.

26. Raskin P, Klaff L, Bergenstal R et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23(11): 1666–1671.

27. Rosenstock J, Schwarz SL, Clark JR CH et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE901) and NPH insulin. Diabetes Care 2001; 24(4): 631–636.

28. 28., Gerstein HC, Bosch J, Dagenais GR et al (ORIGIN Trial Investigators). Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367(4): 319–328.

29. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001; 18(8): 619–625.

30. Bradley C, Gilbride CJB. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Diabetes Obes Metab 2008; 10(Suppl 2): 50–65.

31. Schreiber SA, Ferlinz K, Haak T. The Long-Term Efficacy of Insulin Glargine Plus Oral Antidiabetic Agents in a 32-Month Observational Study of Everyday Clinical Practice. Diabetes Technol Ther 2008; 10(2): 121–127.

32. Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007; 61(12): 2009–2018.

33. SPC inzulin Lantus. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf>.